Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

[1]  B. Knebelmann,et al.  Case report and literature review , 2016, Medicine.

[2]  F. Barkhof,et al.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process , 2015, Nature Reviews Neurology.

[3]  À. Rovira,et al.  Defining high, medium and low impact prognostic factors for developing multiple sclerosis. , 2015, Brain : a journal of neurology.

[4]  M. Sormani,et al.  Subgroups of multiple sclerosis patients with larger treatment benefits: a meta‐analysis of randomized trials , 2015, European journal of neurology.

[5]  À. Rovira,et al.  Brain atrophy in natalizumab-treated patients: A 3-year follow-up , 2015, Multiple sclerosis.

[6]  M. Wattjes,et al.  PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. , 2015, The New England journal of medicine.

[7]  C. Terborg,et al.  PML in a patient with lymphocytopenia treated with dimethyl fumarate. , 2015, The New England journal of medicine.

[8]  D. Arnold,et al.  Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients , 2015, Multiple sclerosis.

[9]  Carsten Lukas,et al.  Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.

[10]  L. Kappos,et al.  Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. , 2015, JAMA neurology.

[11]  M. Wattjes,et al.  PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation , 2014, Case reports in neurological medicine.

[12]  D. Campagnolo,et al.  Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[13]  James McIninch,et al.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients , 2014, Annals of clinical and translational neurology.

[14]  F. Barkhof,et al.  MRI pattern in asymptomatic natalizumab-associated PML , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  Mike P. Wattjes,et al.  Remyelination therapy goes to trial for multiple sclerosis , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[16]  M. Ron,et al.  The grey matter correlates of impaired decision-making in multiple sclerosis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  F. Barkhof,et al.  Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. , 2014, Current opinion in neurology.

[18]  Marco Battaglini,et al.  Automated identification of brain new lesions in multiple sclerosis using subtraction images , 2014, Journal of magnetic resonance imaging : JMRI.

[19]  F. Barkhof,et al.  Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability , 2014, Multiple sclerosis.

[20]  David H. Miller,et al.  Imaging outcomes for trials of remyelination in multiple sclerosis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Carlo Pozzilli,et al.  Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis , 2014, Multiple sclerosis.

[22]  A. Cross,et al.  Established and novel disease‐modifying treatments in multiple sclerosis , 2014, Journal of internal medicine.

[23]  À. Rovira,et al.  Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients , 2014, Multiple sclerosis.

[24]  M. Wattjes,et al.  Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true? , 2014, Annals of neurology.

[25]  B. Hemmer,et al.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview , 2014, Clinical and experimental immunology.

[26]  Olivier Gout,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[27]  F. Barkhof,et al.  Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes , 2014, Multiple sclerosis.

[28]  Turi O. Dalaker,et al.  Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  F. Barkhof,et al.  Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome , 2014, Multiple sclerosis.

[30]  M. Filippi,et al.  Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis , 2014, Multiple sclerosis.

[31]  Marco Battaglini,et al.  Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis , 2014, Multiple sclerosis.

[32]  G. Tedeschi,et al.  Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study , 2014, Multiple sclerosis.

[33]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[34]  Linda J. Scarazzini,et al.  Progressive multifocal leukoencephalopathy after natalizumab discontinuation , 2014, Annals of neurology.

[35]  H. Hartung,et al.  Novel therapeutic options for multiple sclerosis , 2014, Expert review of clinical pharmacology.

[36]  D. Arnold,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[37]  M. Horsfield,et al.  Gray matter damage predicts the accumulation of disability 13 years later in MS , 2013, Neurology.

[38]  F. Barkhof,et al.  The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy , 2013, Multiple sclerosis.

[39]  F. Fazekas,et al.  Tumefactive MS lesions under fingolimod , 2013, Neurology.

[40]  E. Trinka,et al.  Tumefactive MS lesions under fingolimod: A case report and literature review , 2013, Journal of the Neurological Sciences.

[41]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  Maria Pia Sormani,et al.  Defining and scoring response to IFN-β in multiple sclerosis , 2013, Nature Reviews Neurology.

[43]  M. Absinta,et al.  Future MRI tools in multiple sclerosis , 2013, Journal of the Neurological Sciences.

[44]  Jeroen J G Geurts,et al.  Ultra-high field MRI: looking through the ‘macroscope’ , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[45]  M. Filippi,et al.  Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients , 2013, Neurological Sciences.

[46]  G. Comi,et al.  Clinical and MRI predictors of response to interferon‐beta and glatiramer acetate in relapsing–remitting multiple sclerosis patients , 2013, European journal of neurology.

[47]  M. Horsfield,et al.  Ultra-high-field MR imaging in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  J Sastre-Garriga,et al.  Clinical impact of early brain atrophy in clinically isolated syndromes , 2013, Multiple sclerosis.

[49]  B. Banwell,et al.  Standardized magnetic resonance imaging acquisition and reporting in pediatric multiple sclerosis. , 2013, Neuroimaging clinics of North America.

[50]  Douglas L Arnold,et al.  Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[51]  F. Barkhof,et al.  PML in a patient treated with dimethyl fumarate from a compounding pharmacy. , 2013, The New England journal of medicine.

[52]  B Stubinski,et al.  Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.

[53]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[54]  T. Olsson,et al.  Changes to anti-JCV antibody levels in a Swedish national MS cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  Elizabeth Fisher,et al.  Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. , 2013, JAMA neurology.

[56]  D. Altmann,et al.  Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab , 2013, Multiple sclerosis.

[57]  À. Rovira,et al.  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.

[58]  F. Barkhof,et al.  Spinal cord lesions in patients with clinically isolated syndrome , 2013, Neurology.

[59]  D. Reich,et al.  Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. , 2013, Neurology.

[60]  Maja O’Connor.  LONGITUDINAL STUDY , 2013 .

[61]  S. Rauer,et al.  Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod , 2012, Neurology.

[62]  P. Pouwels,et al.  Tumefactive multiple sclerosis lesions under fingolimod treatment , 2012, Neurology.

[63]  M. Filippi,et al.  Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy , 2012, Annals of neurology.

[64]  R. Franklin,et al.  Neuroprotection and repair in multiple sclerosis , 2012, Nature Reviews Neurology.

[65]  M. Sormani,et al.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. , 2012, International journal of MS care.

[66]  M. Calabrese,et al.  Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.

[67]  Xavier Golay,et al.  Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[68]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[69]  Peter A. Calabresi,et al.  Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis , 2012, PloS one.

[70]  R. Lenkinski,et al.  Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS , 2012, Neurology.

[71]  F. Barkhof,et al.  Inflammation high-field magnetic resonance imaging. , 2012, Neuroimaging clinics of North America.

[72]  Massimo Filippi,et al.  Association between pathological and MRI findings in multiple sclerosis , 2012, The Lancet Neurology.

[73]  Massimo Filippi,et al.  New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. , 2012, Expert opinion on medical diagnostics.

[74]  X. Montalban,et al.  Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab , 2012, Multiple sclerosis.

[75]  B. Hemmer,et al.  Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. , 2012, Current pharmaceutical design.

[76]  David H. Miller,et al.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials , 2012, Nature Reviews Neurology.

[77]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[78]  Ponnada A Narayana,et al.  Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis , 2011, Multiple sclerosis.

[79]  Maria Pia Sormani,et al.  Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis , 2011, Multiple sclerosis.

[80]  Massimiliano Calabrese,et al.  Cortical pathology and cognitive impairment in multiple sclerosis , 2011, Expert review of neurotherapeutics.

[81]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[82]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[83]  Robert A. Gross,et al.  Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI , 2011 .

[84]  À. Rovira,et al.  Brainstem lesions in clinically isolated syndromes , 2010, Neurology.

[85]  S. Ropele,et al.  Quantitative MR imaging of brain iron: a postmortem validation study. , 2010, Radiology.

[86]  H. Weiner,et al.  A method for evaluating treatment switching criteria in multiple sclerosis , 2010, Multiple sclerosis.

[87]  M. Battaglini,et al.  Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes , 2010, Neurology.

[88]  Frederik Barkhof,et al.  Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. , 2010, Radiology.

[89]  Stefan Klöppel,et al.  Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures , 2010, NeuroImage.

[90]  D. Altmann,et al.  Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis , 2010, Multiple sclerosis.

[91]  Frederik Barkhof,et al.  Long‐interval T2‐weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials , 2009, Annals of neurology.

[92]  F. Barkhof,et al.  Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla , 2010, European Radiology.

[93]  X. Montalban,et al.  Predicting responders to therapies for multiple sclerosis , 2009, Nature Reviews Neurology.

[94]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.

[95]  F. Barkhof,et al.  Accumulation of cortical lesions in MS: relation with cognitive impairment , 2009, Multiple sclerosis.

[96]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[97]  J. Waggoner,et al.  Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[98]  C. Gerloff,et al.  HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT , 2009, Neurology.

[99]  A. Thompson,et al.  Early MRI in optic neuritis , 2009, Neurology.

[100]  S. Ropele,et al.  Magnetization transfer MR imaging in multiple sclerosis. , 2009, Neuroimaging clinics of North America.

[101]  Marco Rovaris,et al.  Diffusion tensor MR imaging. , 2009, Neuroimaging clinics of North America.

[102]  P. Narayana,et al.  Proton magnetic resonance spectroscopy in multiple sclerosis. , 2009, Neuroimaging clinics of North America.

[103]  R. Rudick,et al.  Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.

[104]  Frederik Barkhof,et al.  Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.

[105]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[106]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[107]  D. Arnold,et al.  Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions , 2008, Annals of neurology.

[108]  À. Rovira,et al.  Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.

[109]  P. Narayana,et al.  Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study , 2008, Multiple sclerosis.

[110]  D. Altmann,et al.  Disability and T 2 MRI lesions: a 20 -year follow-up of patients with relapse onset of multiple sclerosis , 2008 .

[111]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[112]  David H. Miller,et al.  MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation” , 2006, The Lancet Neurology.

[113]  L. Kappos,et al.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.

[114]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[115]  J A Frank,et al.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. , 2006, AJNR. American journal of neuroradiology.

[116]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[117]  P. Matthews,et al.  Risk factors for progression of brain atrophy in aging , 2005, Neurology.

[118]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[119]  David H. Miller,et al.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.

[120]  M. Filippi,et al.  European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. , 2004, Archives of neurology.

[121]  P M Matthews,et al.  Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis , 2004, Annals of neurology.

[122]  C. Polman,et al.  Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. , 2004, Archives of neurology.

[123]  R. Ordidge,et al.  High field MRI correlates of myelin content and axonal density in multiple sclerosis , 2003, Journal of Neurology.

[124]  F. Barkhof,et al.  Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a , 2003, Annals of neurology.

[125]  F. Barkhof,et al.  The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS , 2003, Neurology.

[126]  F. Jolesz,et al.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals , 2003, Neurology.

[127]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[128]  F. Barkhof.  The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.

[129]  S. Dhib-jalbut,et al.  Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis , 2002, Neurology.

[130]  C. Good,et al.  A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis , 2001, Journal of Neurology.

[131]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[132]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[133]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[134]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients , 2000 .

[135]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. , 2000, Multiple sclerosis.

[136]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[137]  F. Barkhof,et al.  The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis , 1999, Neurology.

[138]  C. Moorehead.  All rights reserved , 1997 .

[139]  W. I. McDonald,et al.  Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis , 1996, Neurology.

[140]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[141]  F. Barkhof,et al.  Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. , 1993, Brain : a journal of neurology.

[142]  Ingegerd Nydevik,et al.  A 3-year follow-up , 1992 .

[143]  S. Ropele,et al.  Risk factors for progression of brain atrophy in aging Six-year follow-up of normal subjects , 2022 .

[144]  H. Hyppönen,et al.  a nine-year follow-up survey study , 2022 .

[145]  F. Barkhof,et al.  A powerful tool in diagnosis and prognosis Spinal cord lesions in patients with clinically isolated syndrome : March 8 , 2022 .